Menu
1 min read · estimated
APPROVED USE
What FDA approved
For children aged one year or older with chronic-phase Philadelphia chromosome-positive CML who are newly diagnosed or resistant or intolerant to earlier treatment.
LAMPGEN ANALYSIS
Why it matters
The expanded indication gave younger patients an additional BCR::ABL1-targeted option.
What research teams should watch
Capture phase, prior TKI tolerance and body-size data for pediatric dosing. FDA also approved lower-strength capsules.
PRIMARY RECORDS